Essais liés2clinical trials
VilleKashiwalocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06170788

Ouvrir le site du centre

Essais cliniques associés

2
MoléculeIndication / populationPhaseNCTTitreStatut
Pembrolizumab Cancer Phase 3 NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) RECRUITING
Sacituzumab Tirumotecan Parkinson Phase 3 NCT06170788 TroFuse-007 — Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) RECRUITING